13 Reference
1. Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T.
Remdesivir for treatment of COVID-19; an updated systematic review and
meta-analysis. Eur J Pharmacol. 2021;897:173926.
2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard.https://covid19.who.int/ .
3. Gunduz Gurkan C, Karadogan D, Ufuk F, Cure O, Altinisik G. Management
of Patients with Connective Tissue Disease-associated Interstitial Lung
Diseases During the COVID-19 Pandemic. Turk Thorac J.2021;22(4):346-352.
4. Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with
systemic lupus erythematosus: lessons learned from the inflammatory
disease. Transl Res. 2021;232:13-36.
5. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics
associated with hospitalisation for COVID-19 in people with rheumatic
disease: data from the COVID-19 Global Rheumatology Alliance
physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866.
6. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, But Not TNF
Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients
With Inflammatory Bowel Diseases: Results From an International
Registry. Gastroenterology. 2020;159(2):481-491 e483.
7. Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse
COVID-19 outcomes in patients with psoriasis-insights from a global
registry-based study. J Allergy Clin Immunol. 2021;147(1):60-71.
8. Listing J, Gerhold K, Zink A. The risk of infections associated with
rheumatoid arthritis, with its comorbidity and treatment.Rheumatology (Oxford). 2013;52(1):53-61.
9. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement:
an updated guideline for reporting systematic reviews. Rev Esp
Cardiol (Engl Ed). 2021;74(9):790-799.
10. Robinson PC, Senior staff s, Bursle EC, Infectious diseases p,
Clinical m. Management of autoimmune disease during the COVID-19
pandemic. Aust Prescr. 2020;43(5):146-147.
11. Chimenti MS, Perricone C, Novelli L, et al. Interaction between
microbiome and host genetics in psoriatic arthritis. Autoimmun
Rev. 2018;17(3):276-283.
12. Raychaudhuri SK, Abria C, Mitra A, Raychaudhuri SP. Functional
significance of MAIT cells in psoriatic arthritis. Cytokine.2020;125:154855.
13. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of
SARS-CoV-2 infection-a review of immune changes in patients with viral
pneumonia. Emerg Microbes Infect. 2020;9(1):727-732.
14. Elmas OF, Demirbas A, Kutlu O, et al. Psoriasis and COVID-19: A
narrative review with treatment considerations. Dermatol Ther.2020;33(6):e13858.
15. Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in
COVID-19 vasculitis. Clin Immunol. 2020;217:108487.
16. Song Y, Shen H, Schenten D, Shan P, Lee PJ, Goldstein DR. Aging
enhances the basal production of IL-6 and CCL2 in vascular smooth muscle
cells. Arterioscler Thromb Vasc Biol. 2012;32(1):103-109.
17. Norman PS. Immunobiology: The immune system in health and disease.Journal of Allergy and Clinical Immunology. 1995;96(2):274.
18. McIlwain L, Carter JD, Bin-Sagheer S, Vasey FB, Nord J.
Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary
to infliximab. Journal of clinical gastroenterology.2003;36(5):411-413.
19. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS,
Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19
patients: emerging evidence and call for action. Br J Haematol.2020;189(5):846-847.
20. Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of
COVID-19 treated with the complement C3 inhibitor AMY-101. Clin
Immunol. 2020;215:108450.
21. Goodman KE, Magder LS, Baghdadi JD, et al. Impact of Sex and
Metabolic Comorbidities on Coronavirus Disease 2019 (COVID-19) Mortality
Risk Across Age Groups: 66 646 Inpatients Across 613 U.S. Hospitals.Clin Infect Dis. 2021;73(11):e4113-e4123.
22. Strangfeld A, Schafer M, Gianfrancesco MA, et al. Factors associated
with COVID-19-related death in people with rheumatic diseases: results
from the COVID-19 Global Rheumatology Alliance physician-reported
registry. Ann Rheum Dis. 2021;80(7):930-942.
23. Kan M, Himes BE. Insights into glucocorticoid responses derived from
omics studies. Pharmacol Ther. 2021;218:107674.
24. Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic
Mechanisms of Glucocorticoids. Trends Endocrinol Metab.2018;29(1):42-54.
25. D’Silva KM, Wallace ZS. COVID-19 and Disease-Modifying
Anti-rheumatic Drugs. Curr Rheumatol Rep. 2021;23(5):28.
26. Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly
patients: Characteristics and prognostic factors based on 4-week
follow-up. J Infect. 2020;80(6):639-645.
27. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco
C. Clinical course of COVID-19 in a series of patients with chronic
arthritis treated with immunosuppressive targeted therapies. Ann
Rheum Dis. 2020;79(5):667-668.
28. Haberman RH, Castillo R, Chen A, et al. COVID-19 in Patients With
Inflammatory Arthritis: A Prospective Study on the Effects of
Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical
Outcomes. Arthritis Rheumatol. 2020;72(12):1981-1989.
29. Migkos MP, Kaltsonoudis E, Pelechas E, et al. Use of conventional
synthetic and biologic disease-modifying anti-rheumatic drugs in
patients with rheumatic diseases contracting COVID-19: a single-center
experience. Rheumatol Int. 2021;41(5):903-909.
30. Wang W, Ye L, Ye L, et al. Up-regulation of IL-6 and TNF-alpha
induced by SARS-coronavirus spike protein in murine macrophages via
NF-kappaB pathway. Virus Res. 2007;128(1-2):1-8.
31. Kaneko N, Kuo HH, Boucau J, et al. Loss of Bcl-6-Expressing T
Follicular Helper Cells and Germinal Centers in COVID-19. Cell.2020;183(1):143-157 e113.
32. Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-alpha and
IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality
in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell.2021;184(1):149-168 e117.
33. Robinson PC, Liew DFL, Liew JW, et al. The Potential for Repurposing
Anti-TNF as a Therapy for the Treatment of COVID-19. Med (N Y).2020;1(1):90-102.
34. Consortium WHOST, Pan H, Peto R, et al. Repurposed Antiviral Drugs
for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J
Med. 2021;384(6):497-511.
35. Group RC, Horby P, Mafham M, et al. Effect of Hydroxychloroquine in
Hospitalized Patients with Covid-19. N Engl J Med.2020;383(21):2030-2040.
36. Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in
Hospitalized Patients with Covid-19. N Engl J Med.2020;383(21):2030-2040.
37. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases
Society of America Guidelines on the Treatment and Management of
Patients with COVID-19. Clin Infect Dis. 2020.
38. Chen TH, Cheng HT, Yeh CT. Epidemiology changes in peptic ulcer
diseases 18 years apart explored from the genetic aspects of
Helicobacter pylori. Transl Res. 2021;232:115-120.
39. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali
R. COVID-19 infection and rheumatoid arthritis: Faraway, so close!Autoimmun Rev. 2020;19(5):102523.
40. Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19:
Comparison to RT-PCR. Radiology. 2020;296(2):E115-e117.
41. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR
Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of
1014 Cases. Radiology. 2020;296(2):E32-e40.